How PsiOxus is building a gene therapy cancer platform on its oncolytic virus
Having taken its lead oncolytic virus into the clinic, PsiOxus Therapeutics Ltd. is building an immuno-oncology platform that uses engineered versions of the vector to selectively target multiple genes at a time to tumor cells wherever they reside.
The idea behind the company’s T-SIGn platform is that by delivering to tumor cells genes that interplay with immuno-oncology pathways, the company can either weaponize the cells to modify the tumor microenvironment or alter their properties to make them more vulnerable to immune attack.
PsiOxus’ lead compound, enadenotucirev, is an oncolytic Ad11p/Ad3 chimeric group B adenovirus in Phase I/II testing for platinum-resistant ovarian cancer and Phase I testing for advanced solid tumors. Data for the two trials are expected in 1H19 and 2H19, respectively.
Rather than using the virus primarily for its oncolytic activity, PsiOxus is using it as a delivery vehicle. The company has created “armed” versions of enadenotucirev that travel through the circulation and carry up to four exogenous genes to tumor cells, including metastases.
PsiOxus has one T-SIGn program in the clinic and four disclosed